Protective effects of valsartan administration on doxorubicin‑induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling
Related Experiment Video
Updated: Dec 7, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dong Cheng1, Libo Chen1, Wencheng Tu1
1Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China.
Abstract:
Clinical application of doxorubicin (DOX) is hampered by its potential cardiotoxicity, however angiotensin receptor blockers could attenuate DOX‑induced cardiomyopathy. The present study tested the hypothesis that simultaneous administration of valsartan (Val) with DOX could prevent DOX‑induced myocardial injury by modulating myocardial NAD(P)H oxidase (NOX) expression in rats. Eight‑week‑old male Sprague‑Dawley rats were randomly divided into control (CON), DOX, and DOX+Val groups. After 10 weeks, surviving rats underwent echocardiography examination, myocardial mRNA and protein expression detection of NOX1, NOX2 and NOX4. H9C2 cells were used to perform in vitro experiments, reactive oxygen species (ROS) production and apoptosis were observed under the conditions of down‑ or upregulation of NOX2 and NOX4 in DOX‑ and DOX+Val‑treated H9C2 cells. Cardiac function was significantly improved, pathological lesion and collagen volume fraction were significantly reduced in the DOX+Val group compared with the DOX group (all P<0.05). Myocardial protein and mRNA expression of NOX2 and NOX4 was significantly downregulated in DOX+Val group compared with in the DOX group (all P<0.05). In vitro, ROS production and apoptosis in DOX‑treated H9C2 cells was significantly reduced by NOX2‑small interfering (si)RNA and NOX4‑siRNA, and significantly increased by overexpressing NOX2 and NOX4. To conclude, Val applied simultaneously with DOX could prevent DOX‑induced myocardial injury and reduce oxidative stress by downregulating the myocardial expression of NOX2 and NOX4 in rats.
Insights
Valsartan prevents doxorubicin-induced heart damage by reducing oxidative stress and downregulating myocardial NAD(P)H oxidase 2 and 4 expression in rats.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Doxorubicin (DOX) chemotherapy causes cardiotoxicity, limiting its clinical use.
- Angiotensin receptor blockers may mitigate DOX-induced cardiomyopathy.
- NAD(P)H oxidase (NOX) enzymes are implicated in DOX-induced oxidative stress.
Purpose of the Study:
- To investigate if valsartan (Val) co-administration with DOX prevents myocardial injury.
- To determine if valsartan modulates myocardial NAD(P)H oxidase (NOX) expression.
- To assess the role of NOX2 and NOX4 in DOX-induced oxidative stress and apoptosis.
Main Methods:
- Rats were divided into control, DOX, and DOX+Val groups for 10 weeks.
- Echocardiography, and myocardial mRNA/protein expression of NOX1, NOX2, and NOX4 were analyzed.
- In vitro studies used H9C2 cells to examine reactive oxygen species (ROS) and apoptosis under varying NOX2/NOX4 levels.
Main Results:
- DOX+Val group showed improved cardiac function, reduced pathological lesions, and collagen volume fraction compared to the DOX group.
- Myocardial NOX2 and NOX4 mRNA and protein expression were significantly downregulated in the DOX+Val group.
- In vitro, NOX2/NOX4 knockdown reduced ROS and apoptosis in DOX-treated cells, while overexpression increased them.
Conclusions:
- Valsartan co-administered with doxorubicin prevents DOX-induced myocardial injury in rats.
- Valsartan mitigates DOX cardiotoxicity by reducing oxidative stress.
- This protective effect is mediated by the downregulation of myocardial NOX2 and NOX4 expression.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers

